4WEALTH Advisors Inc. Trims Stake in Intuitive Surgical, Inc. (NASDAQ:ISRG)

4WEALTH Advisors Inc. decreased its position in Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) by 49.0% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 829 shares of the medical equipment provider's stock after selling 795 shares during the period. 4WEALTH Advisors Inc.'s holdings in Intuitive Surgical were worth $411,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of ISRG. Brighton Jones LLC increased its stake in Intuitive Surgical by 24.9% in the fourth quarter. Brighton Jones LLC now owns 3,672 shares of the medical equipment provider's stock valued at $1,916,000 after purchasing an additional 731 shares in the last quarter. Bank Pictet & Cie Europe AG grew its position in Intuitive Surgical by 0.5% in the 4th quarter. Bank Pictet & Cie Europe AG now owns 190,969 shares of the medical equipment provider's stock worth $99,678,000 after purchasing an additional 883 shares in the last quarter. TD Private Client Wealth LLC boosted its stake in Intuitive Surgical by 8.1% in the fourth quarter. TD Private Client Wealth LLC now owns 3,988 shares of the medical equipment provider's stock valued at $2,082,000 after acquiring an additional 299 shares during the last quarter. Plancorp LLC purchased a new stake in shares of Intuitive Surgical during the 4th quarter valued at approximately $224,000. Finally, Hillsdale Investment Management Inc. lifted its stake in shares of Intuitive Surgical by 40.1% during the 4th quarter. Hillsdale Investment Management Inc. now owns 699 shares of the medical equipment provider's stock valued at $365,000 after buying an additional 200 shares in the last quarter. Institutional investors and hedge funds own 83.64% of the company's stock.

Analyst Ratings Changes

ISRG has been the topic of a number of research analyst reports. Robert W. Baird decreased their price target on shares of Intuitive Surgical from $600.00 to $575.00 and set an "outperform" rating on the stock in a report on Wednesday, April 23rd. Evercore ISI raised their price target on shares of Intuitive Surgical from $470.00 to $550.00 and gave the stock an "in-line" rating in a report on Tuesday, July 8th. Piper Sandler reaffirmed an "overweight" rating and issued a $595.00 target price (up from $575.00) on shares of Intuitive Surgical in a research report on Wednesday. Royal Bank Of Canada lifted their price target on shares of Intuitive Surgical from $605.00 to $615.00 and gave the company an "outperform" rating in a research report on Wednesday. Finally, Wells Fargo & Company lifted their price target on shares of Intuitive Surgical from $559.00 to $599.00 and gave the company an "overweight" rating in a research report on Wednesday. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and fourteen have given a buy rating to the stock. Based on data from MarketBeat, Intuitive Surgical has a consensus rating of "Moderate Buy" and a consensus price target of $590.91.

Intuitive Surgical Stock Performance

Shares of ISRG stock traded down $9.49 during trading hours on Wednesday, reaching $501.51. The company had a trading volume of 3,692,259 shares, compared to its average volume of 1,677,429. The business has a fifty day moving average price of $535.90 and a 200-day moving average price of $536.29. Intuitive Surgical, Inc. has a one year low of $425.00 and a one year high of $616.00. The firm has a market cap of $179.75 billion, a PE ratio of 73.53, a price-to-earnings-growth ratio of 5.47 and a beta of 1.64.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last announced its quarterly earnings results on Tuesday, July 22nd. The medical equipment provider reported $2.19 EPS for the quarter, topping analysts' consensus estimates of $1.93 by $0.26. Intuitive Surgical had a net margin of 28.41% and a return on equity of 14.43%. The firm had revenue of $2.44 billion during the quarter, compared to analyst estimates of $2.35 billion. During the same period in the previous year, the business posted $1.78 earnings per share. The business's revenue for the quarter was up 21.4% on a year-over-year basis. Equities research analysts forecast that Intuitive Surgical, Inc. will post 6.43 EPS for the current year.

Insider Buying and Selling at Intuitive Surgical

In other Intuitive Surgical news, EVP Gary Loeb sold 1,700 shares of the company's stock in a transaction that occurred on Friday, April 25th. The shares were sold at an average price of $513.18, for a total value of $872,406.00. Following the completion of the transaction, the executive vice president directly owned 2,245 shares in the company, valued at $1,152,089.10. This represents a 43.09% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Robert Desantis sold 188 shares of the company's stock in a transaction that occurred on Monday, April 28th. The stock was sold at an average price of $515.91, for a total transaction of $96,991.08. Following the completion of the transaction, the executive vice president owned 5,224 shares of the company's stock, valued at approximately $2,695,113.84. The trade was a 3.47% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 4,998 shares of company stock valued at $2,611,577. 0.70% of the stock is owned by corporate insiders.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.